TB-500
Also known as: Thymosin Beta-4
limited human dataNot FDA approvedResearch only
Mechanism of Action
TB-500 is commonly discussed as a synthetic fragment associated with thymosin beta-4 biology. The best-established mechanism for thymosin beta-4 is actin binding and cytoskeletal remodeling, which can influence cell migration, wound repair, and tissue remodeling; direct human protocol evidence for TB-500 itself remains limited.
Key Citations
- Thymosin beta 4 sequesters the majority of G-actin in resting human polymorphonuclear leukocytes.
The Journal of cell biology · 1992 · PMID 1447300
Published Dose Range
No published dosing data available.
Published Cycle Range
Short4 wks
Typical5 wks
Long8 wks
4-6 weeks per cycle. Run 2-3x per year for maintenance.
Administration
Routessubcutaneous, intramuscular
FrequencyNo data
Spreads systemically unlike BPC-157's more localized action
Safety Profile
Pregnancy / breastfeeding
No data — consult clinician
Common Misconceptions
- Often recommended in stacking articles without specific dosing — readers told to stack without knowing how much
Commonly Stacked With
BPC-157CJC-1295Tesamorelin
Next Steps
Sign in to calculate your dose, add this compound to your stack, and check for interactions with your current cabinet.